Table 3.
Unadjusted Biochemically-confirmed 7-Day Point-Prevalence Abstinence Rates at Weeks 4, 8, and 26 by Treatment Condition and Menthol Status (N=1439)
| Treatment Condition |
Week 4 | Week 8 | Week 26 | |||
|---|---|---|---|---|---|---|
| Non-Menthol Smokers1 |
Menthol Smokers2 |
Non-Menthol Smokers1 |
Menthol Smokers2 |
Non-Menthol Smokers1 |
Menthol Smokers2 |
|
| Total Sample | 51.4% | 42.7% | 47.9% | 38.9% | 35.9% | 29.9% |
| Placebo | 34.9% | 25.7% | 34.0% | 24.3% | 24.5% | 20.3% |
| Bupropion | 47.4% | 41.4% | 43.0% | 37.9% | 34.1% | 31.0% |
| Nicotine Lozenge | 46.8% | 30.1% | 45.3% | 32.7% | 38.1% | 27.4% |
| Nicotine Patch | 55.9% | 47.2% | 49.7% | 37.7% | 36.6% | 30.2% |
| Bupropion + Lozenge | 59.0% | 53.6% | 53.2% | 49.1% | 35.3% | 32.7% |
| Patch + Lozenge | 59.3% | 53.8% | 58.0% | 47.2% | 43.3% | 34.9% |
| All Active Treatments | 53.8% | 45.0% | 50.0% | 40.8% | 37.6% | 31.2% |
| Monotherapy Treatments3 | 50.1% | 39.4% | 46.1% | 36.1% | 36.3% | 29.6% |
| Combination Therapies4 | 59.2% | 53.7% | 55.7% | 48.2% | 39.5% | 33.8% |
1
N=814;
2
N=625;
3
Bupropion only, Nicotine Lozenge only, and Nicotine Patch only;
4
Bupropion + Nicotine Lozenge and Nicotine Patch + Nicotine Lozenge